Veranex, a tech-enabled service provider dedicated to the medical technology industry, has acquired an ecosystem of full-service medical device consultancy companies, providing regulatory and clinical affairs, quality assurance, and biocompatibility services for medical devices and in vitro diagnostic (IVD) devices.
Panchenko Vladimir Shutterstock
1475723714
M&A concept
Based in Sweden, this ecosystem includes Devicia, a full-service partner offering clinical expertise; Clarvin, a provider of strategic guidance in regulatory affairs and quality assurance; and affiliate companies Kickfile, Lea Reg, and Limulus Bio. Together with the recent acquisition of Swiss-based Medidee, these companies expand Veranex’s European reach and build regulatory, clinical, and quality service segments. This specifically strengthens Veranex’s medical device regulation (MDR) and in vitro diagnostic regulation (IVDR) strategy, adding expertise in biological evaluations and medical device software and expanding infrastructure and designating local representation in the European Union and United Kingdom.
Veranex CEO David Dockhorn said: “This group of companies, led by Devicia and Clarvin, shares the same goal as Veranex: working with our clients to achieve and accelerate medtech innovation. Devicia, Clarvin, and their affiliate companies all focus exclusively on medical devices and IVD, providing strategic guidance and informed execution across a number of areas, including clinical trial, medical writing, regulatory strategies, toxicology assessments, designated local representation, and system technologies that bolster Veranex’s full-service medtech capabilities and solutions.”
The group of companies adds three locations across Europe and the U.S. to Veranex’s global footprint.
Devicia CEO Elisabeth Liljensten said: “We are extremely excited about the opportunity to support clients even more comprehensively with our full-service medical device and IVD services, and a significantly stronger global presence. We strongly believe that a global perspective and broad geographic footprint provides strategic value to market access for our clients.”
Clarvin CEO Åsa Runnäs added: “Since the first interaction with Veranex, we realised we shared the same vision for the best way to help our clients — with a combination of top regulatory intelligence, expert knowledge within different areas, and true global reach.”
Alvarez & Marsal (A&M) served as financial advisor and McDermott Will & Emery (MWE) served as legal advisor to Veranex on this transaction. Christopher Fägerskiöld AB served as financial advisor and Kanter as legal advisor to Devicia and Clarvin group. Financial details are not being disclosed.
